8 completed, 2 unknown, 1 withdrawn. 7 Phase 1, 6 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Withdrawn 1 |
| Phase 2 | 6 | Completed 4, Unknown 2 |
| Phase 3 | 2 | Completed 2 |
Follow AIDSVAX: new trials by email Literature Review of AIDSVAX trials Research Report on AIDSVAX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B) - HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 160 | 2018-01-16 | 2023-03-14 |
| Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine ALVAC-HIV (vCP2438), Bivalent Subtype C gp120/MF59, Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension - HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 132 | 2017-06-19 | 2026-07-24 |
| Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa ALVAC-HIV (vCP2438), Bivalent Subtype C gp120/MF59, Placebo - HIV Infections | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 5404 | 2016-10-26 | 2026-05-04 |
| A Safety and Immune Response Study of 2 Experimental HIV Vaccines ALVAC-HIV, Bivalent Subtype C gp120/MF59®, ALVAC-HIV (vCP2438) Placebo - HIV Infection | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 252 | 2015-02-02 | 2021-11-05 |
| Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E ALVAC-HIV, AIDSVAX B/E, ALVAC-HIV Placebo - HIV Infections | Phase 2 | Unknown | U.S. Army Medical Research and Development Command | 360 | 2013-09-24 | 2021-03-26 |
| Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults ALVAC-HIV, AIDSVAX B/E, Placebo for ALVAC-HIV - HIV Infection | Phase 1 | Completed | HIV Vaccine Trials Network | 202 | 2013-06-18 | 2019-06-21 |
| Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144 ALVAC-HIV, AIDSVAX B/E, ALVAC-HIV Placebo - HIV Infections | Phase 2 | Unknown | U.S. Army Medical Research and Development Command | 162 | 2012-04-01 | 2020-11-03 |
| Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm ALVAC-HIV (vCP205) - HIV Infections, HIV Seronegativity | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 18 | 2006-06-01 | 2012-10-29 |
| HIV Vaccine Trial in Thai Adults ALVAC-HIV vCP1521 + AIDSVAX, ALVAC Placebo + AIDSVAX Placebo - HIV Infection | Phase 3 | Completed | U.S. Army Medical Research and Development Command | 16402 | 2003-10-01 | 2019-04-24 |
| Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa DNA-HIV-PT123 vaccine, NYVAC-HIV-PT1 vaccine, NYVAC-HIV-PT4 vaccine - HIV Infections | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-10-15 | ||
| Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers ALVAC-HIV vCP1521, ALVAC HIV-1 vCP1521 - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2021-11-01 |
HIV Infections (11) · Acquired Immunodeficiency Syndrome (1)
National Institute of Allergy and Infectious Diseases (NIAID) (7) · U.S. Army Medical Research and Development Command (3) · HIV Vaccine Trials Network (1)
South Africa (4) · Thailand (3) · United States (2) · Zimbabwe (2) · Mozambique (1) · Tanzania (1) · Uganda (1) · Zambia (1)
Glenda Gray, MD (2) · Supachai Rerks-Ngarm, MD (2) · Francis Mmiro, MBChB, FRCOG (1) · Kathy Mngadi (1) · Laura Guay, MD (1) · Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD (1) · Magdalena Sobieszczyk (1) · Paul Goepfert (1) · Peter Anton, MD (1) · Punnee Pitisuttithum, MD, DTM&H (1) · Z Mike Chirenje (1)
PMID 40190112, PMID 31999736, PMID 34895272, PMID 37256916, PMID 19843557, PMID 22205930, PMID 23221981, PMID 24091694, PMID 24504509, PMID 24558403, PMID 24829343, PMID 25350851, PMID 25401780, PMID 28131393, PMID 28235027, PMID 28329190, PMID 29702672, PMID 29898870, PMID 32035516, PMID 32092060, PMID 37260254, PMID 37355583, PMID 37795976, PMID 38502656, PMID 38772835, PMID 39302924, PMID 41121745
R01AI050467 (1)